Shanghai-based gene therapy specialist Belief BioMed Group (BBM) has announced a strategic partnership with Japan’s Takeda Pharmaceutical Company (TYO: 4502), granting Takeda commercialization rights for its investigational product, BBM-H901. This agreement encompasses the territories of mainland China, Hong Kong, and Macau. Financial details of the partnership have not been disclosed.
Innovative Gene Therapy for Hemophilia B
BBM-H901 is being developed as both a prophylactic and treatment option for bleeding in adults with hemophilia B. Notably, it is recognized as the first adeno-associated virus (AAV) gene therapy for hemophilia B to receive Investigational New Drug (IND) approval for a registrational clinical study in China. The clinical results for BBM-H901 were published in prestigious journals, including The Lancet Hematology and the New England Journal of Medicine, in 2022. During this period, the therapy also received breakthrough therapy designation (BTD) in China.
Addressing Hemophilia B in China
Hemophilia B is a recessive genetic disorder linked to the X chromosome, resulting in coagulation dysfunction due to insufficient levels of coagulation factor IX (FIX). In China, approximately 38 million individuals are registered as suffering from this condition, highlighting the urgent need for effective treatment options like BBM-H901.-Fineline Info & Tech
